Perturbation of Rb, p53, and Brca1 or Brca2 Cooperate in Inducing Metastatic Serous Epithelial Ovarian Cancer

被引:95
|
作者
Szabova, Ludmila [1 ]
Yin, Chaoying [4 ]
Bupp, Sujata [1 ]
Guerin, Theresa M. [1 ]
Schlomer, Jerome J. [1 ]
Householder, Deborah B. [1 ]
Baran, Maureen L. [1 ]
Yi, Ming [2 ]
Song, Yurong [3 ,4 ]
Sun, Wenping [2 ]
McDunn, Jonathan E. [5 ]
Martin, Philip L. [1 ]
Van Dyke, Terry [1 ,3 ,4 ]
Difilippantonio, Simone [1 ]
机构
[1] NCI Federick, Ctr Adv Preclin Res, SAIC, Frederick Natl Lab Canc Res, Frederick, MD 21702 USA
[2] NCI Federick, Adv Biomed Comp Ctr, SAIC, Frederick Natl Lab Canc Res, Frederick, MD 21702 USA
[3] NCI Frederick, Mouse Canc Genet Program, Frederick, MD USA
[4] Univ N Carolina, Dept Genet, Chapel Hill, NC USA
[5] Metabolon Inc, Durham, NC USA
关键词
MOUSE MODEL; CONDITIONAL INACTIVATION; FALLOPIAN-TUBE; PERITONEAL MESOTHELIOMA; PAPILLARY CARCINOMA; DISTANT METASTASES; MUTATIONS; INDUCTION; WOMEN; P130;
D O I
10.1158/0008-5472.CAN-11-3834
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The majority of human high-grade serous epithelial ovarian cancer (SEOC) is characterized by frequent mutations in p53 and alterations in the RB and FOXM1 pathways. A subset of human SEOC harbors a combination of germline and somatic mutations as well as epigenetic dysfunction for BRCA1/2. Using Cre-conditional alleles and intrabursal induction by Cre-expressing adenovirus in genetically engineered mice, we analyzed the roles of pathway perturbations in epithelial ovarian cancer initiation and progression. Inactivation of RB-mediated tumor suppression induced surface epithelial proliferation with progression to stage I carcinoma. Additional biallelic inactivation and/or missense p53 mutation in the presence or absence of Brca1/2 caused progression to stage IV disease. As in human SEOC, mice developed peritoneal carcinomatosis, ascites, and distant metastases. Unbiased gene expression and metabolomic profiling confirmed that Rb, p53, and Brca1/2-triple mutant tumors aligned with human SEOC, and not with other intraperitoneal cancers. Together, our findings provide a novel resource for evaluating disease etiology and biomarkers, therapeutic evaluation, and improved imaging strategies in epithelial ovarian cancer. Cancer Res; 72(16); 4141-53. (C) 2012 AACR.
引用
收藏
页码:4141 / 4153
页数:13
相关论文
共 50 条
  • [41] Three novel BRCA1/BRCA2 mutations in breast/ovarian cancer families in Croatia
    Levanat, Sonja
    Musani, Vesna
    Cvok, Mirela Levacic
    Susac, Ilona
    Sabol, Maja
    Ozretic, Petar
    Car, Diana
    Eljuga, Domagoj
    Eljuga, Ljerka
    Eljuga, Damir
    GENE, 2012, 498 (02) : 169 - 176
  • [42] Surgically treated ovarian endometriosis association with BRCA1 and BRCA2 mutations
    Aviel-Ronen, Sarit
    Soriano, David
    Shmuel, Elyasaf
    Schonman, Ron
    Rosenblatt, Kinneret
    Zadok, Oranit
    Vituri, Aya
    Seidman, Daniel
    Barshack, Iris
    Cohen, Yoram
    PATHOLOGY RESEARCH AND PRACTICE, 2014, 210 (04) : 250 - 255
  • [43] Enhanced response rate to pegylated liposomal doxorubicin in high grade serous ovarian carcinomas harbouring BRCA1 and BRCA2 aberrations
    Hollis, Robert L.
    Meynert, Alison M.
    Churchman, Michael
    Rye, Tzyvia
    Mackean, Melanie
    Nussey, Fiona
    Arends, Mark J.
    Sims, Andrew H.
    Semple, Colin A.
    Herrington, C. Simon
    Gourley, Charlie
    BMC CANCER, 2018, 18
  • [44] Timing Is Everything: Brca2 and p53 Mutations in Pancreatic Cancer
    Morton, Jennifer P.
    Steele, Colin W.
    Sansom, Owen J.
    GASTROENTEROLOGY, 2011, 140 (04) : 1143 - 1146
  • [45] Reliability of Tumor Testing Compared to Germline Testing for Detecting BRCA1 and BRCA2 Mutations in Patients with Epithelial Ovarian Cancer
    Bekos, Christine
    Grimm, Christoph
    Kranawetter, Marlene
    Polterauer, Stephan
    Oberndorfer, Felicitas
    Tan, Yen
    Muellauer, Leonhard
    Singer, Christian F.
    JOURNAL OF PERSONALIZED MEDICINE, 2021, 11 (07):
  • [46] Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma
    Soslow, Robert A.
    Han, Guangming
    Park, Kay J.
    Garg, Karuna
    Olvera, Narciso
    Spriggs, David R.
    Kauff, Noah D.
    Levine, Douglas A.
    MODERN PATHOLOGY, 2012, 25 (04) : 625 - 636
  • [47] BRCA1 and BRCA2 mutations in Belgian families with a history of breast and/or ovarian
    Sibille-Hoang, C
    Froment, O
    de ter Beerst, AJ
    Lepiece, V
    Huberlant, G
    Blauwaert, G
    Vindevoghel, A
    Canon, JL
    Gillerot, Y
    EUROPEAN JOURNAL OF CANCER PREVENTION, 1998, 7 : S3 - S5
  • [48] Comparing Prognosis for BRCA1, BRCA2, and Non-BRCA Breast Cancer
    Antunes Meireles, Pedro
    Fragoso, Sofia
    Duarte, Teresa
    Santos, Sidonia
    Bexiga, Catarina
    Nejo, Priscila
    Luis, Ana
    Mira, Beatriz
    Miguel, Isalia
    Rodrigues, Paula
    Vaz, Fatima
    CANCERS, 2023, 15 (23)
  • [49] Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants
    Li, Shuai
    Silvestri, Valentina
    Leslie, Goska
    Rebbeck, Timothy R.
    Neuhausen, Susan L.
    Hopper, John L.
    Nielsen, Henriette Roed
    Lee, Andrew
    Yang, Xin
    McGuffog, Lesley
    Parsons, Michael T.
    Andrulis, Irene L.
    Arnold, Norbert
    Belotti, Muriel
    Borg, Ake
    Buecher, Bruno
    Buys, Saundra S.
    Caputo, Sandrine M.
    Chung, Wendy K.
    Colas, Chrystelle
    Colonna, Sarah, V
    Cook, Jackie
    Daly, Mary B.
    de la Hoya, Miguel
    de Pauw, Antoine
    Delhomelle, Helene
    Eason, Jacqueline
    Engel, Christoph
    Evans, D. Gareth
    Faust, Ulrike
    Fehm, Tanja N.
    Fostira, Florentia
    Fountzilas, George
    Frone, Megan
    Garcia-Barberan, Vanesa
    Garre, Pilar
    Gauthier-Villars, Marion
    Gehrig, Andrea
    Glendon, Gord
    Goldgar, David E.
    Golmard, Lisa
    Greene, Mark H.
    Hahnen, Eric
    Hamann, Ute
    Hanson, Helen
    Hassan, Tiara
    Hentschel, Julia
    Horvath, Judit
    Izatt, Louise
    Janavicius, Ramunas
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (14) : 1529 - +
  • [50] Genes beyond BRCA1 and BRCA2 for hereditary breast cancer
    Simon, Katharina
    Geigl, Jochen B.
    Pristauz, Gunda
    WIENER MEDIZINISCHE WOCHENSCHRIFT, 2010, 160 (19-20) : 478 - 482